B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 1.792 NOK 1.59% Market Closed
Market Cap: 70m NOK

Bergenbio ASA
Investor Relations

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.

Show more
Loading

Earnings Calls

2023 Q2
Aug 18, 2023
Show Transcript
Previous
Next
Mall Growth and Office Drop Amid Reopening
2023 Q2
Aug 18, 2023

After reopening its borders with Mainland China and benefiting from the government's Consumption Voucher Scheme, local retail thrived, particularly at Langham Place Mall, with tenant sales jumping 66.3%—substantially better than the market's 20.7% rise. The mall's rental income rose by 12.3%, with turnover rent soaring to HKD 114 million or 10% of rental income. In contrast, the office segment faltered, with both properties experiencing negative rental reversions and general occupancy challenges, notably Three Garden Road which saw a 9% rental income drop. Overall, the company reported a 2.4% decline in total rental income to HKD 1,168 million, a 4.7% decrease in net property income to HKD 995 million, a 12.3% cut in distributable income to HKD 617 million, and a 12.6% fall in distribution per unit to HKD 0.0927. Despite a promising first half, tenant sales growth is expected to moderate, and management is strategizing to increase fixed-rate debt in light of rising interest rates and upcoming debt maturity in 2024 to stabilize finances.

Show Full Analysis

Management

Mr. Martin Olin
Chief Executive Officer
No Bio Available
Mr. Rune Skeie
Chief Financial Officer
No Bio Available
Ms. Cristina Oliva M.D.
Chief Medical Officer
No Bio Available
Graham Morell
Head of IR
No Bio Available
Ms. Gayle M. Mills M.B.A
Chief Business Officer
No Bio Available
Dr. Akil Jackson
Medical Director
No Bio Available

Contacts

Address
HORDALAND
Bergen
Jonas Lies vei 91
Contacts
+4755961159.0
www.bergenbio.com